Re-appointment of Dr. Pankaj J. Shah (DIN:02836324) as Managing Director & CEO of the Company for a period of three (3) years i.e from August 01, 2025 to July 31, 2028.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aspira Pathlab & Diagnostics has re-appointed Dr. Pankaj Shah (DIN: 02836324) as its Managing Director & CEO for a fresh three-year term running from August 1, 2025 to July 31, 2028. The re-appointment was first approved by the Nomination & Remuneration Committee and Board on May 16, 2025, and then confirmed by shareholders through a special resolution passed via postal ballot on July 10, 2025. Dr. Shah, a pathologist with over 43 years of experience, has been the key leader of the company and is not related to any other director or KMP. He is also not debarred from holding office by SEBI or any other authority.
Continuity at the top: shareholders have endorsed the existing leadership for another three years, which signals stability in strategy and operations. For retail investors, this is a routine governance update with no change in management direction.